DRMA Stock: Dermata Therapeutics, Inc. Stock Price, Analysis & Insights
Get live drma stock price $1.86, comprehensive Dermata Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time drma stock data and investment insights.
Loading chart...
Company Overview
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.
Company Information
- CEO
- Gerald T. Proehl
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
Contact Information
- Website
- https://www.dermatarx.com
- Address
- 3525 Del Mar Heights Road
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 0.1)
✓ Lower volatility stock (Beta: 0.53) may provide portfolio stability
Business Model & Strategy
Dermata Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Gerald T. Proehl, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Dermata Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 1.3 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Dermata Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Dermata Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Dermata Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Dermata Therapeutics, Inc.
- ⚠Investors should consider how Dermata Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
1.27M
P/E Ratio
0.12
Beta
0.53
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 1.27M market capitalization
- Trading Volume: 671.81K shares traded today
- Price Range: 52-week range of $1.80 - $23.70
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. (DRMA) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 1.27M, the company represents a significant player in its market. The stock is currently trading at $1.86 with a negativedaily change of 21.52%.
The company's 8 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 0.12, beta of 0.53, and 52-week price range from $1.80 to $23.70when evaluating investment opportunities.
Why Invest in Dermata Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Gerald T. Proehl
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.